[go: up one dir, main page]

DK3359160T3 - Farnesoid x receptor modulatorer - Google Patents

Farnesoid x receptor modulatorer Download PDF

Info

Publication number
DK3359160T3
DK3359160T3 DK16854420.3T DK16854420T DK3359160T3 DK 3359160 T3 DK3359160 T3 DK 3359160T3 DK 16854420 T DK16854420 T DK 16854420T DK 3359160 T3 DK3359160 T3 DK 3359160T3
Authority
DK
Denmark
Prior art keywords
farnesoid
receptor modulators
modulators
receptor
Prior art date
Application number
DK16854420.3T
Other languages
English (en)
Inventor
Roberto Pellicciari
Antimo Gioiello
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3359160T3 publication Critical patent/DK3359160T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16854420.3T 2015-10-07 2016-10-07 Farnesoid x receptor modulatorer DK3359160T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238246P 2015-10-07 2015-10-07
PCT/US2016/055980 WO2017062763A1 (en) 2015-10-07 2016-10-07 Farnesoid x receptor modulators

Publications (1)

Publication Number Publication Date
DK3359160T3 true DK3359160T3 (da) 2021-11-22

Family

ID=58488545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16854420.3T DK3359160T3 (da) 2015-10-07 2016-10-07 Farnesoid x receptor modulatorer

Country Status (27)

Country Link
US (2) US11034717B2 (da)
EP (2) EP3359160B1 (da)
JP (2) JP7021080B2 (da)
KR (1) KR20180061351A (da)
CN (1) CN108348530B (da)
AR (1) AR106293A1 (da)
AU (1) AU2016335765B2 (da)
BR (1) BR112018006892B1 (da)
CA (1) CA3000881C (da)
CL (1) CL2018000883A1 (da)
CO (1) CO2018003728A2 (da)
CR (1) CR20180201A (da)
DK (1) DK3359160T3 (da)
EA (1) EA038665B1 (da)
EC (1) ECSP18030284A (da)
ES (1) ES2898705T3 (da)
HK (1) HK1253558A1 (da)
IL (1) IL258359B2 (da)
MA (2) MA42339A1 (da)
MX (1) MX2018004186A (da)
PH (1) PH12018500777A1 (da)
SV (1) SV2018005662A (da)
TN (1) TN2018000106A1 (da)
TW (1) TW201718621A (da)
UA (1) UA123948C2 (da)
WO (1) WO2017062763A1 (da)
ZA (1) ZA201802901B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215179A4 (en) 2014-11-06 2018-07-25 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2015353473A1 (en) 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
RU2017130466A (ru) 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
LT3277286T (lt) 2015-03-31 2021-07-26 Enanta Pharmaceuticals, Inc. Tulžies rūgšties dariniai kaip fxr/tgr agonistai, ir jų panaudojimo būdai
EP3359160B1 (en) 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10584145B2 (en) 2016-11-29 2020-03-10 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
ES2971092T3 (es) 2017-04-07 2024-06-03 Enanta Pharm Inc Procedimiento para la preparación de derivados de ácidos biliares de carbamato de sulfonilo
CA3067219A1 (en) * 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
BR112020001362A2 (pt) 2017-07-24 2020-08-11 Intercept Pharmaceuticals, Inc. derivados de ácido biliar isotopicamente marcados
EP3730509B1 (en) * 2017-12-19 2024-10-16 Xi'an Biocare Pharma Ltd. Compound for treating metabolic diseases and preparation method and use thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN114144185A (zh) 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2599481A (en) * 1948-09-28 1952-06-03 Ciba Pharm Prod Inc Reduction of steroid epoxides
EP0101554B1 (en) * 1982-07-29 1986-10-15 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1223313B (it) 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
EP2040713B1 (en) * 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
JP5535233B2 (ja) * 2008-11-19 2014-07-02 インターセプト ファーマシューティカルズ, インコーポレイテッド Tgr5モジュレーターおよびその使用方法
JP2015521621A (ja) 2012-06-19 2015-07-30 インターセプト ファーマシューティカルズ, インコーポレイテッド オベチコール酸の調製、使用および固体形態
NZ708501A (en) * 2012-11-28 2019-03-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
PL3360882T3 (pl) * 2013-05-14 2021-10-25 Intercept Pharmaceuticals, Inc. 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu X
US9351083B2 (en) 2013-10-17 2016-05-24 Turtle Beach Corporation Transparent parametric emitter
US11578097B2 (en) * 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
AU2015353473A1 (en) * 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
EP3359160B1 (en) * 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
WO2017062856A1 (en) 2015-10-07 2017-04-13 Stoller Enterprises, Inc. Managing ethylene in plants using a synergistic agricultural formula comprising diacyl or diary urea and at least one metal complex
PL3426348T3 (pl) * 2016-03-11 2022-01-03 Intercept Pharmaceuticals, Inc. Pochodna 3-dezoksylowa i jej kompozycje farmaceutyczne
CA3067219A1 (en) * 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives

Also Published As

Publication number Publication date
ECSP18030284A (es) 2018-05-31
CA3000881A1 (en) 2017-04-13
AU2016335765B2 (en) 2022-01-06
EP3359160A4 (en) 2019-06-05
EP3359160B1 (en) 2021-08-25
CR20180201A (es) 2018-08-24
WO2017062763A1 (en) 2017-04-13
EA201890899A1 (ru) 2018-09-28
JP7021080B2 (ja) 2022-02-16
KR20180061351A (ko) 2018-06-07
CN108348530A (zh) 2018-07-31
MA42339A1 (fr) 2019-01-31
MX2018004186A (es) 2018-05-17
EA038665B1 (ru) 2021-09-30
UA123948C2 (uk) 2021-06-30
IL258359B2 (en) 2023-11-01
IL258359B1 (en) 2023-07-01
US11034717B2 (en) 2021-06-15
MA45761A (fr) 2021-04-21
AR106293A1 (es) 2018-01-03
BR112018006892A2 (pt) 2018-10-16
PH12018500777A1 (en) 2018-10-29
ES2898705T3 (es) 2022-03-08
EP3359160A1 (en) 2018-08-15
CA3000881C (en) 2024-03-19
CO2018003728A2 (es) 2018-07-31
IL258359A (en) 2018-06-28
TW201718621A (zh) 2017-06-01
HK1253558A1 (zh) 2019-06-21
NZ741058A (en) 2024-05-31
CL2018000883A1 (es) 2018-06-29
CN108348530B (zh) 2023-09-29
BR112018006892B1 (pt) 2023-04-11
EP3981779A1 (en) 2022-04-13
TN2018000106A1 (en) 2019-10-04
US20170101434A1 (en) 2017-04-13
SV2018005662A (es) 2018-12-14
ZA201802901B (en) 2019-07-31
JP2019210297A (ja) 2019-12-12
JP2018530559A (ja) 2018-10-18
AU2016335765A1 (en) 2018-04-19
US20210269475A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
DK3359160T3 (da) Farnesoid x receptor modulatorer
MA43382A (fr) Modulateurs des récepteurs des chimiokines
MA53943A (fr) Modulateurs de ror-gamma
EP3442971A4 (en) ESTROGEN RECEPTOR MODULATORS
DK3331876T3 (da) Modulators of ror-gamma
MA55328A (fr) Modulateurs de ror-gamma
HK1255160A1 (zh) 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途
MA42061A (fr) Modulateurs de k-ras
DK3297438T3 (da) Ccr2-modulatorer
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
DK3848027T3 (da) Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
HK1248678A1 (zh) 核受體調節劑
EP3069836C0 (de) Überlappungsvorrichtung
BR112017024750A2 (pt) dispositivo de cofragem
DK3322543T3 (da) Vibrerende aktuator
EP3565543A4 (en) MU TYPE OPIOID RECEIVER MODULATORS
MA52555A (fr) Modulateurs du récepteur des oestrogènes
DE112016005541A5 (de) Arylierungsverfahren
ME03379B (me) Pozitivni alosterni modulatori muskarinskog m1 receptora
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
EP3374386C0 (en) PROTEASE-ACTIVATED RECEPTOR TYPE 2 MODULATORS
BR112017024381A2 (pt) dispositivo
HUE046307T2 (hu) A3 adenozin receptorok tiazol modulátorai
DK3581572T3 (da) Adenosin-A3-receptormodulatorer
EP3332776A4 (en) Patch